173 related articles for article (PubMed ID: 17027659)
1. New drugs for the treatment of advanced-stage diffuse large cell lymphomas.
O'Connor OA; Hamlin P
Semin Hematol; 2006 Oct; 43(4):251-61. PubMed ID: 17027659
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
4. Targeting histones and proteasomes: new strategies for the treatment of lymphoma.
O'Connor OA
J Clin Oncol; 2005 Sep; 23(26):6429-36. PubMed ID: 16155030
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
[TBL] [Abstract][Full Text] [Related]
6. Drug resistance in diffuse large B-cell lymphoma.
Wilson WH
Semin Hematol; 2006 Oct; 43(4):230-9. PubMed ID: 17027657
[TBL] [Abstract][Full Text] [Related]
7. Pralatrexate: an emerging new agent with activity in T-cell lymphomas.
O'Connor OA
Curr Opin Oncol; 2006 Nov; 18(6):591-7. PubMed ID: 16988580
[TBL] [Abstract][Full Text] [Related]
8. Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.
Delmonte A; Ghielmini M; Sessa C
Oncologist; 2009 May; 14(5):511-25. PubMed ID: 19411316
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapies for B-cell non-Hodgkin lymphoma.
Briones J
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1305-16. PubMed ID: 19761434
[TBL] [Abstract][Full Text] [Related]
10. The molecular background of aggressive B cell lymphomas as a basis for targeted therapy.
de Jong D; Balagué Ponz O
J Pathol; 2011 Jan; 223(2):274-82. PubMed ID: 21125680
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis].
Tagawa H
Gan To Kagaku Ryoho; 2007 Jul; 34(7):975-82. PubMed ID: 17637530
[TBL] [Abstract][Full Text] [Related]
12. New drug therapies in peripheral T-cell lymphoma.
Howman RA; Prince HM
Expert Rev Anticancer Ther; 2011 Mar; 11(3):457-72. PubMed ID: 21417858
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 antisense therapy in B-cell malignancies.
Chanan-Khan A
Blood Rev; 2005 Jul; 19(4):213-21. PubMed ID: 15784299
[TBL] [Abstract][Full Text] [Related]
14. BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas.
Perez-Rosado A; Artiga M; Vargiu P; Sanchez-Aguilera A; Alvarez-Barrientos A; Piris M
J Pathol; 2008 Mar; 214(4):498-507. PubMed ID: 18189332
[TBL] [Abstract][Full Text] [Related]
15. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Jazirehi AR; Vega MI; Bonavida B
Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
[TBL] [Abstract][Full Text] [Related]
16. Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas.
Sutherland AP; Mackay F; Mackay CR
Pharmacol Ther; 2006 Dec; 112(3):774-86. PubMed ID: 16863659
[TBL] [Abstract][Full Text] [Related]
17. Targeting aggressive B-cell lymphomas with cell-penetrating peptides.
Melnick A
Biochem Soc Trans; 2007 Aug; 35(Pt 4):802-6. PubMed ID: 17635152
[TBL] [Abstract][Full Text] [Related]
18. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
19. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
[TBL] [Abstract][Full Text] [Related]
20. Targeted treatment and new agents in diffuse large B-cell lymphoma.
Leonard JP; Martin P; Barrientos J; Elstrom R
Semin Hematol; 2008 Jul; 45(3 Suppl 2):S11-6. PubMed ID: 18760704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]